 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Evoxac |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608025 |
| Pregnancy category |
|
| Routes of administration | By mouth (capsules) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | <20% |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C10H17NOS |
| Molar mass | 199.31 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Cevimeline (trade nameEvoxac) is a synthetic analog of the natural alkaloidmuscarine with a particular agonistic effect onM1 andM3 receptors. It is used in the treatment ofdry mouth andSjögren's disease.
Cevimeline is used in the treatment ofxerostomia (dry mouth)[1][2] andSjögren's syndrome.[1] It increases the production of saliva.[2]
Known side effects includenausea,vomiting,diarrhea, excessivesweating,rash,headache,runny nose,cough,drowsiness,hot flashes,blurred vision, anddifficulty sleeping.[3]
Contraindications includeasthma andangle closure glaucoma.[citation needed]
Cevimeline is a cholinergic agonist.[2] It has a particular effect onM1 andM3 receptors.[2] By activating the M3 receptors of theparasympathetic nervous system, cevimeline stimulates secretion by thesalivary glands, thereby alleviating dry mouth.
